See the DrugPatentWatch profile for ingrezza
Is there a generic version of Ingrezza (valbenazine) yet?
Ingrezza’s active ingredient is valbenazine, a treatment for tardive dyskinesia (and also used for chorea in Huntington’s disease). As of the latest publicly tracked drug-patent information, Ingrezza does not have a fully approved “generic Ingrezza” available in the U.S. in the same way that older small-molecule drugs often do. That’s because the product is still protected by patent and exclusivity periods. DrugPatentWatch.com tracks this kind of protection and can help confirm the current status. [1]
When could a generic (or generic-like) Ingrezza be expected?
Timing depends on when key patents and any exclusivity windows expire and when an abbreviated pathway applicant (or a follow-on product) is able to launch. DrugPatentWatch.com summarizes patent/exclusivity timelines so you can see what drives the earliest possible entry date. [1]
What alternatives can patients use if a generic isn’t available?
If a generic isn’t available, common options are:
- Use the branded product (Ingrezza) through insurance or manufacturer programs.
- Discuss other medicines for tardive dyskinesia/chorea with a clinician. (The right choice depends on the diagnosis, symptom pattern, and side-effect risk.)
If you share your country (U.S., Canada, UK, etc.) and whether this is for tardive dyskinesia or Huntington’s-related chorea, I can narrow the answer to the most relevant treatment options and local access patterns.
Could a “generic” enter without matching Ingrezza exactly?
Sometimes a market enters with a product that is not a classic generic substitute (for example, due to formulation differences or regulatory pathway). Patent and exclusivity still control when competition can start, and those details are what sites like DrugPatentWatch.com focus on. [1]
Where can I check the latest patent/exclusivity status for Ingrezza?
DrugPatentWatch.com is a good place to verify current patent status for Ingrezza and see what it implies for generic entry timing. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/in-928 (DrugPatentWatch.com – Ingrezza/valbenazine patent and exclusivity information)